TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02366689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/fluoride toothpaste
Description: Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stannous fluoride toothpaste
Description: Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluoride only toothpaste
Description: Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetylpyridinium chloride mouthwash
Description: Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride only mouthwash
Description: Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
Study: NCT02907723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Recording
Description: the device records movements during patients' sleep
Study: NCT03926832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea Syndrome (OSAS) management when moderate-to-severe. Subjects with OSA will be trained in the use of CPAP and will be instructed to use it every night for 3 months. These subjects will then return for a post-treatment completion of questionnaires (ESS and FAS) and compliance analysis.
Study: NCT02040129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof Toric IOL
Description: Lens implantation following cataract surgery
Study: NCT03415932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education
Description: Health information by a multimodal team
Study: NCT03482518

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: custom slippers with perforated synthetic leather cover.
Description: the intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: custom slippers with perforated synthetic leather cover.
Description: the intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover.
Study: NCT02644668

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Granules for oral suspension (placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 150 mg
Description: Granules for oral suspension, 18.7% reldesemtiv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 450 mg
Description: Granules for oral suspension, 56.0% reldesemtiv
Study: NCT02865304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar
Study: NCT01405482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline injection
Description: 10 cc of Normal Saline will be injected under EMG guidance into the Anterior and Middle Scalenes and Pectoralis Minor muscle of individual diagnosed with Thoracic Outlet Syndrome.
Study: NCT02819973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care 3
Study: NCT04347369

Intervention type: OTHER
Intervention: other
Description: clinical diagnosis
Study: NCT00304798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital admission
Study: NCT02923011

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRgFUS
Description: Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CTgRFA
Description: Computed tomography-guided radiofrequency ablation of osteoid osteoma
Study: NCT02533440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EXPAREL and Local Anesthetics
Description: Patients will receive EXPAREL and local anesthetics, as well as opioid and non-opioid analgesics prescription, (only use if needed, for post surgical pain)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Opioid and Local Anesthetics
Description: Patients will receive local anesthetics, as well as oral opioid or non-opioid analgesics, (only use if needed, for post surgical pain)
Study: NCT03995485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-136 capsule
Description: KW-136 60 mg was provided in a single capsule of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir was provided in a single tablet of 400 mg.
Study: NCT01847586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation
Description: PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Paired Associative Stimulation-Control
Description: PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Paired Associative Stimulation-Control
Description: PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
Study: NCT01097889

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified blended foods, Corn Soya Bean Flour (CSB) with oil.
Description: A daily ration equivalent of 300g CSB and 32g vegetable oil Bi-weekly distribution of premix of 4.2kg CSB with 0.5L vegetable oil. Estimated 1413 kcal, 47g protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUSF (ready-to-use supplementary foods) Supplementary Plumpy®
Description: Peanut-based fortified supplement~One 92g sachet eaten throughout the day Bi-weekly distributions of 14 sachets 500 kcal and 13g protein
Study: NCT05514561

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal calprotectin
Description: To calculate the diagnostic accuracy of fecal calprotectin in the diagnosis of significant ileocolonic lesions
Study: NCT02212431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine
Description: Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
Study: NCT00478361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride
Description: Gemcitabine 900 mg/m\^2 IV over 90 minutes repeat every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135 mg/m\^2 IV over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: Doxorubicin 40 mg/m\^2 IV over 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Subcutaneously injection on day 1.
Study: NCT04074213

Intervention type: DRUG
Intervention: Clozapine
Description: Clozapine treatment
Study: NCT01847196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel® Catheter
Description: The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
Study: NCT00691145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: transdermal
Study: NCT04513340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Description: CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Description: CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Description: CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Description: CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
Study: NCT03622333

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Research of constitutional genetic alterations
Description: Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis
Study: NCT04641572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choose comfortable position
Description: Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions will be taken by the participant during labor.Then the researcher will register the time ( minutes/hours) will be taken and which that will be more preferable by the participant
Study: NCT04443283

Intervention type: OTHER
Intervention: No intervention
Description: This is a observation study, with no intervention

Intervention type: OTHER
Intervention: No intervention
Description: This is a observation study, with no intervention
Study: NCT03077633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Cerclage placement
Description: Cervical Cerclage placement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone
Description: 200mg tab of vaginal progesterone administered daily from time of randomization until delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal Progesterone
Description: 200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
Study: NCT03214757

Intervention type: OTHER
Intervention: treatment of anemia.
Description: drug treatment of anemia.
Study: NCT02535000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: duloxetine 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT02012179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Description: Low sodium diet (65 mmol or 1500 mg/day)
Study: NCT03349177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 500mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2(TC), 100mg/m2(EC-T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2(TC), 100mg/m2(EC-T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/m2(FEC), 600mg/m2(EC-T and TC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/m2(FEC), 600mg/m2(EC-T and TC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/m2(FEC), 600mg/m2(EC-T and TC)
Study: NCT01072019

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument
Description: Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument
Description: Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.
Study: NCT02732587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saracatinib
Description: Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
Study: NCT03757585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Treatment with Omega-3 Fatty Acids + Inositol
Description: Open-label Treatment with Omega-3 Fatty Acids + Inositol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Treatment with N-acetylcysteine
Description: Open-label Treatment with acetylcysteine
Study: NCT01545687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 lozenge
Description: Dissolved orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dissolved orally
Study: NCT03428659

Intervention type: OTHER
Intervention: Data acquisition of functional abilities in sub-acute stroke
Description: MRI data, motor evoked potentials, gait function and behavior data acquisition
Study: NCT03381885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Nudge
Description: Clinicians ordering medium or high scoring imaging studies could bypass the usual mandatory phone call to radiology.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Standard Procedure
Description: Clinicians ordering imaging studies required mandatory phone to radiology
Study: NCT03621085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: A total of 20 mg of Ketamine Hydrochloride will be administered intravenously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo
Study: NCT02785133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVL1000 Treatment Station
Description: Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Solution
Description: 150 ml of 0.9% Sodium Chloride Solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Catheterization
Description: 20-gauge 1.0 catheter
Study: NCT01416376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2379
Description: SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
Study: NCT01312779

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of CEP Magna Mitral Model 7000TFX
Description: Heart valve surgery: CEP Magna Mitral Model 7000 TFX
Study: NCT04156074

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D enriched (20 mcg/day) olive oil emulsion drink
Description: Vitamin D enriched (20 mcg/day) olive oil emulsion drink. 30 mL drink daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D enriched (20 mcg/day) coconut oil emulsion drink
Description: Vitamin D enriched (20 mcg/day) coconut oil emulsion drink 30 mL drink daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo coconut oil emulsion drink
Description: Placebo coconut oil emulsion drink 30 mL drink daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement (20 mcg/day)
Description: Vitamin D supplement (20 mcg/day) Pill consumed daily
Study: NCT00786110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
Study: NCT01916785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
Study: NCT03945344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Oral capsule 20 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Oral capsule 20 μg
Study: NCT01513785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole and Amoxicillin
Description: Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin and Rabeprazole
Description: Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
Study: NCT01944228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Nerve Stimulation
Description: 30 minutes of vagal nerve stimulation using a catheter in the IJV

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Catheter placed in the IJV without stimulation
Study: NCT04149899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WB007 0.05%
Description: WB007 Ophthalmic Solution 0.05%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WB007 0.15%
Description: WB007 Ophthalmic Solution 0.15%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WB007 0.15%
Description: WB007 Ophthalmic Solution 0.15%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WB007 0.4%
Description: WB007 Ophthalmic Solution 0.4%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WB007 0.4%
Description: WB007 Ophthalmic Solution 0.4%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5%
Description: Timolol Maleate 0.5% Ophthalmic Solution
Study: NCT05514561

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal immunochemical test
Description: To calculate the diagnostic accuracy of the fecal immunochemical test in the diagnosis of significant ileocolonic lesions
Study: NCT04050852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen Treatments
Description: Antisense oligonucleotide, which targets the SMN2 pre-mRNA, particularly exon 7.
Study: NCT02224651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Subjects will receive sequential single escalating doses of 1-1000 mg of Immediate Release of PF-06650833 (as solution/suspension) under fed and / or fasted conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Subjects will receive sequential single escalating doses of 10-500 mg of Modified Release of PF-06650833 (as capsule) under fed and / or fasted conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
Study: NCT04633122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: Oral kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
Study: NCT02999373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood Mononuclear Cells Therapy
Description: Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection
Study: NCT01047085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: impedance pH measurement
Description: Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: impedance pH measurement
Description: Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
Study: NCT04391556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firmagon
Description: 120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
Study: NCT01919957

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Study: NCT01155063

Intervention type: OTHER
Intervention: Aromasin (exemestane)
Description: Aromasin (exemestane), tablets 25 mg, once a day
Study: NCT04835298

Intervention type: OTHER
Intervention: Dyspnea
Description: questionnaires